论文部分内容阅读
目的 :观察地尔硫治疗急性冠状动脉综合征的剂量及临床疗效。方法 :2 5例急性冠状动脉综合征患者静脉滴注地尔硫 1～ 5 μg·kg-1·min-1,持续用药 4 8h。结果 :ST段抬高型心绞痛及非ST段抬高型心绞痛用药前后心绞痛发作次数明显减少 (P <0 .0 5 ) ;地尔硫治疗ST段抬高型心绞痛较非ST段抬高型心绞痛更为有效 (P <0 .0 5 )。地尔硫可不同程度地降低心率、血压及心肌氧耗量 ,其中用药后 2h及 12h心肌氧耗量明显下降 (P <0 .0 5 )。结论 :静脉滴注地尔硫 1～ 3μg·kg-1·min-1可有效改善各种类型心绞痛的发作 ,且其不良反应小、安全性高
Objective: To observe the dose and clinical efficacy of diltiazem in the treatment of acute coronary syndrome. Methods: Twenty-five patients with acute coronary syndrome were treated with intravenous diltiazem 1 ~ 5 μg · kg-1 · min-1 for 48 h. Results: The number of angina pectoris in patients with ST-segment elevation angina pectoris and non-ST segment elevation angina pectoris was significantly decreased (P <0.05); Diltiazem treatment of ST-segment elevation angina pectoris Angina was more effective (P <0.05). Diltiazem could reduce heart rate, blood pressure and myocardial oxygen consumption to some extent. The myocardial oxygen consumption decreased obviously at 2h and 12h after treatment (P <0.05). Conclusion: Intravenous diltiazem 1 ~ 3μg · kg-1 · min-1 can effectively improve the onset of various types of angina, and its adverse reactions are small, high safety